Click here to close now.




















Welcome!

News Feed Item

BerGenBio Presents Data at AACR-ISLAC Conference on the Molecular Origins of Lung Cancer

Highlights BGB324's potential as a novel treatment for NSCLC in patients with acquired drug resistance

BERGEN, Norway, January 9, 2014 /PRNewswire/ --

 


Highlights BGB324's potential as a novel treatment for NSCLC in patients with acquired drug resistance

BerGenBio AS ("BerGenBio" or the "Company"), an oncology biopharmaceutical company, announces that preclinical data demonstrating that its lead compound, BGB324 has potential application as a novel treatment for non-small cell lung cancer (NSCLC) was presented in a poster at the American Association of Cancer Research and The International Association for the Study of Lung Cancer's (AACR-ISLAC) joint conference on the Molecular Origins of Lung Cancer, which took place on January 6-9, 2014.[1]

The study was conducted in collaboration with investigators at the University of Bergen and University of Texas Southwestern Medical Center in Dallas and highlights the potential of BGB324, a first-in-class, highly selective small molecule inhibitor of the Axl receptor tyrosine kinase, as a novel therapeutic option for NSCLC.

The study evaluated the effects of BGB324 on NSCLC cells in in vitro 3D assays and in mouse xenograft models, in combination with targeted chemotherapeutic agents. The results demonstrated that BGB324 can overcome acquired drug resistance in in vivo models of NSCLC and suggests that BGB324 may be effective in treating patients with drug-resistant NSCLC, caused by long-term use of the EGFR inhibitor erlotinib (Roche's Tarceva), the current first line treatment for EGFR mutated NSCLC patients. The results also demonstrated that treatment with BGB324 could enhance the antitumor activities of chemotherapeutic and targeted agents such as docetaxel and bevacizumab (Sanofi's Taxotere and Roche's Avastin) in patients with NSCLC.

BGB324 is the only selective Axl inhibitor in clinical development having recently completed a phase Ia clinical trial. Phase Ib clinical trials are planned in acute myeloid leukemia and NSCLC in 2014.

Professor James Lorens, Department of Biomedicine and Centre for Cancer Biomarkers, University of Bergen, Norway and Chief Scientific Officer and co-founder of BerGenBio, commented: "The results presented in this poster support our view that targeting Axl is a promising new approach to treating drug resistant cancers. There is an urgent unmet medical need for new therapies that are able to overcome drug resistance, particularly in non-small cell lung cancer. This data suggests that BGB324 has the potential to do this and we look forward to exploring this further in the clinic."

1. Katarzyna Wnuk-Lipinska, Gro Gausdal, Tone Sandal et al.  Selective Small Molecule AXL Inhibitor BGB324 Overcomes Acquired Drug Resistance in Non-Small Cell Lung Carcinoma Models, AACR-ISLAC joint conference on the Molecular Origins of Lung Cancer, January 6-9, 2014.

-Ends-

 

About the Axl kinase receptor

Axl is a member of the Tyro3, Axl, Mer receptor (TAMR) tyrosine kinase family and is a fundamental receptor to cancer biology. It plays a crucial role in the epithelial-mesenchymal transition (EMT) which is a key driver of metastasis (cancer spread) and a mechanism of drug-resistance. The Axl receptor is regarded as one of the most promising new therapeutic targets for cancer drug development.

About Non-Small Cell Lung Cancer

Non-small cell lung cancer (NSCLC) is an aggressive form of cancer, classified as any type of epithelial lung cancer other than small cell lung carcinoma. About 85% to 90% of lung cancers are NSCLC. There are 3 primary types of NSCLC: adenocarcinoma, squamous cell carcinoma and large cell carcinoma. The American Cancer Society estimates that 228,190 new cases of NSCLC will be diagnosed in 2013.

About BerGenBio AS

BerGenBio AS is a biopharmaceutical company located in Bergen, Norway. The company is committed to developing first in class therapeutics that inhibit EMT, preventing the formation of cancer stem cells and disrupting the important mechanisms of acquired cancer drug resistance. The company is founded on proprietary platform technology called CellSelect™, which uses information from RNAi screening studies to identify and validate novel drug targets and biomarkers. BGB324 is the first compound in BerGenBio's pipeline to enter clinical trials, with additional compounds and drug targets at different stages of preclinical development.


SOURCE BerGenBio

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Skeuomorphism usually means retaining existing design cues in something new that doesn’t actually need them. However, the concept of skeuomorphism can be thought of as relating more broadly to applying existing patterns to new technologies that, in fact, cry out for new approaches. In his session at DevOps Summit, Gordon Haff, Senior Cloud Strategy Marketing and Evangelism Manager at Red Hat, discussed why containers should be paired with new architectural practices such as microservices rathe...
Whether you like it or not, DevOps is on track for a remarkable alliance with security. The SEC didn’t approve the merger. And your boss hasn’t heard anything about it. Yet, this unruly triumvirate will soon dominate and deliver DevSecOps faster, cheaper, better, and on an unprecedented scale. In his session at DevOps Summit, Frank Bunger, VP of Customer Success at ScriptRock, will discuss how this cathartic moment will propel the DevOps movement from such stuff as dreams are made on to a prac...
SYS-CON Events announced today that IceWarp will exhibit at the 17th International Cloud Expo®, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. IceWarp, the leader of cloud and on-premise messaging, delivers secured email, chat, documents, conferencing and collaboration to today's mobile workforce, all in one unified interface
It’s been proven time and time again that in tech, diversity drives greater innovation, better team productivity and greater profits and market share. So what can we do in our DevOps teams to embrace diversity and help transform the culture of development and operations into a true “DevOps” team? In her session at DevOps Summit, Stefana Muller, Director, Product Management – Continuous Delivery at CA Technologies, answered that question citing examples, showing how to create opportunities for ...
WebRTC has had a real tough three or four years, and so have those working with it. Only a few short years ago, the development world were excited about WebRTC and proclaiming how awesome it was. You might have played with the technology a couple of years ago, only to find the extra infrastructure requirements were painful to implement and poorly documented. This probably left a bitter taste in your mouth, especially when things went wrong.
SYS-CON Events announced today that DataClear Inc. will exhibit at the 17th International Cloud Expo®, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. The DataClear ‘BlackBox’ is the only solution that moves your PC, browsing and data out of the United States and away from prying (and spying) eyes. Its solution automatically builds you a clean, on-demand, virus free, new virtual cloud based PC outside of the United States, and wipes it clean...
Too often with compelling new technologies market participants become overly enamored with that attractiveness of the technology and neglect underlying business drivers. This tendency, what some call the “newest shiny object syndrome,” is understandable given that virtually all of us are heavily engaged in technology. But it is also mistaken. Without concrete business cases driving its deployment, IoT, like many other technologies before it, will fade into obscurity.
Any Ops team trying to support a company in today’s cloud-connected world knows that a new way of thinking is required – one just as dramatic than the shift from Ops to DevOps. The diversity of modern operations requires teams to focus their impact on breadth vs. depth. In his session at DevOps Summit, Adam Serediuk, Director of Operations at xMatters, Inc., will discuss the strategic requirements of evolving from Ops to DevOps, and why modern Operations has begun leveraging the “NoOps” approa...
While many app developers are comfortable building apps for the smartphone, there is a whole new world out there. In his session at @ThingsExpo, Narayan Sainaney, Co-founder and CTO of Mojio, will discuss how the business case for connected car apps is growing and, with open platform companies having already done the heavy lifting, there really is no barrier to entry.
SYS-CON Events announced today that G2G3 will exhibit at SYS-CON's @DevOpsSummit Silicon Valley, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. Based on a collective appreciation for user experience, design, and technology, G2G3 is uniquely qualified and motivated to redefine how organizations and people engage in an increasingly digital world.
As more intelligent IoT applications shift into gear, they’re merging into the ever-increasing traffic flow of the Internet. It won’t be long before we experience bottlenecks, as IoT traffic peaks during rush hours. Organizations that are unprepared will find themselves by the side of the road unable to cross back into the fast lane. As billions of new devices begin to communicate and exchange data – will your infrastructure be scalable enough to handle this new interconnected world?
This Enterprise Strategy Group lab validation report of the NEC Express5800/R320 server with Intel® Xeon® processor presents the benefits of 99.999% uptime NEC fault-tolerant servers that lower overall virtualized server total cost of ownership. This report also includes survey data on the significant costs associated with system outages impacting enterprise and web applications. Click Here to Download Report Now!
SYS-CON Events announced today that Micron Technology, Inc., a global leader in advanced semiconductor systems, will exhibit at the 17th International Cloud Expo®, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. Micron’s broad portfolio of high-performance memory technologies – including DRAM, NAND and NOR Flash – is the basis for solid state drives, modules, multichip packages and other system solutions. Backed by more than 35 years of tech...
SYS-CON Events announced today that Pythian, a global IT services company specializing in helping companies leverage disruptive technologies to optimize revenue-generating systems, has been named “Bronze Sponsor” of SYS-CON's 17th Cloud Expo, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. Founded in 1997, Pythian is a global IT services company that helps companies compete by adopting disruptive technologies such as cloud, Big Data, advance...
SYS-CON Events announced today the Containers & Microservices Bootcamp, being held November 3-4, 2015, in conjunction with 17th Cloud Expo, @ThingsExpo, and @DevOpsSummit at the Santa Clara Convention Center in Santa Clara, CA. This is your chance to get started with the latest technology in the industry. Combined with real-world scenarios and use cases, the Containers and Microservices Bootcamp, led by Janakiram MSV, a Microsoft Regional Director, will include presentations as well as hands-on...